{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:59:53Z","timestamp":1790841593619,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2019FI_B2 00061"],"award-info":[{"award-number":["2019FI_B2 00061"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2019FI_B2 00061"],"award-info":[{"award-number":["2019FI_B2 00061"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["201607.10"],"award-info":[{"award-number":["201607.10"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["603003"],"award-info":[{"award-number":["603003"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To optimize gene delivery to myelinating Schwann cells we compared clinically relevant AAV serotypes and injection routes. AAV9 and AAVrh10 vectors expressing either EGFP or the neuropathy-associated gene <jats:italic>GJB1<\/jats:italic>\/Connexin32 (Cx32) under a myelin specific promoter were injected intrathecally or intravenously in wild type and <jats:italic>Gjb1-<\/jats:italic>null mice, respectively. Vector biodistribution in lumbar roots and sciatic nerves was higher in AAVrh10 injected mice while EGFP and Cx32 expression rates and levels were similar between the two serotypes. A gradient of biodistribution away from the injection site was seen with both intrathecal and intravenous delivery, while similar expression rates were achieved despite higher vector amounts injected intravenously. Quantified immune cells in relevant tissues were similar to non-injected littermates. Overall, AAV9 and AAVrh10 efficiently transduce Schwann cells throughout the peripheral nervous system with both clinically relevant routes of administration, although AAV9 and intrathecal injection may offer a more efficient approach for treating demyelinating neuropathies.<\/jats:p>","DOI":"10.1038\/s41598-021-02694-1","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T11:03:04Z","timestamp":1638442984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery"],"prefix":"10.1038","volume":"11","author":[{"given":"A.","family":"Kagiava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tryfonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Leal-Juli\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sargiannidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. A.","family":"Kleopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"2694_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143419","author":"J Morena","year":"2019","unstructured":"Morena, J., Gupta, A. & Hoyle, J. C. Charcot-marie-tooth: From molecules to therapy. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20143419 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2694_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2019.146572","volume":"1728","author":"I Sargiannidou","year":"2020","unstructured":"Sargiannidou, I., Kagiava, A. & Kleopa, K. A. Gene therapy approaches targeting Schwann cells for demyelinating neuropathies. Brain Res. 1728, 146572. https:\/\/doi.org\/10.1016\/j.brainres.2019.146572 (2020).","journal-title":"Brain Res."},{"key":"2694_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135357","volume":"742","author":"M Stavrou","year":"2021","unstructured":"Stavrou, M., Sargiannidou, I., Christofi, T. & Kleopa, K. A. Genetic mechanisms of peripheral nerve disease. Neurosci. Lett. 742, 135357. https:\/\/doi.org\/10.1016\/j.neulet.2020.135357 (2021).","journal-title":"Neurosci. Lett."},{"key":"2694_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00250-0","author":"A Kagiava","year":"2021","unstructured":"Kagiava, A. et al. AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy. Gene. Ther. https:\/\/doi.org\/10.1038\/s41434-021-00250-0 (2021).","journal-title":"Gene. Ther."},{"key":"2694_CR5","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell, J. R. et al. Assessment of systemic delivery of raavrh74.mhck7.micro-dystrophin in children with Duchenne muscular dystrophy: A nonrandomized controlled trial. JAMA Neurol. 77, 1122\u20131131. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1484 (2020).","journal-title":"JAMA Neurol."},{"key":"2694_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00231-3","author":"B Ozes","year":"2021","unstructured":"Ozes, B. et al. AAV1NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1. Gene. Ther. https:\/\/doi.org\/10.1038\/s41434-021-00231-3 (2021).","journal-title":"Gene. Ther."},{"key":"2694_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/brain\/awz064","volume":"142","author":"N Schiza","year":"2019","unstructured":"Schiza, N. et al. Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy. Brain 142, 1227\u20131241. https:\/\/doi.org\/10.1093\/brain\/awz064 (2019).","journal-title":"Brain"},{"key":"2694_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41434-018-0009-8","volume":"25","author":"ME Yalvac","year":"2018","unstructured":"Yalvac, M. E. et al. AAV1NT-3 gene therapy increases muscle fiber diameter through activation of mTOR pathway and metabolic remodeling in a CMT mouse model. Gene Ther. 25, 129\u2013138. https:\/\/doi.org\/10.1038\/s41434-018-0009-8 (2018).","journal-title":"Gene Ther."},{"key":"2694_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/gt.2012.101","volume":"20","author":"SJ Gray","year":"2013","unstructured":"Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J. & Jude Samulski, R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 20, 450\u2013459. https:\/\/doi.org\/10.1038\/gt.2012.101 (2013).","journal-title":"Gene Ther."},{"key":"2694_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3233\/JHD-180302","volume":"7","author":"E Mondo","year":"2018","unstructured":"Mondo, E. et al. Selective neuronal uptake and distribution of AAVrh8, AAV9, and AAVrh10 in sheep after intra-striatal administration. J. Huntingtons. Dis. 7, 309\u2013319. https:\/\/doi.org\/10.3233\/JHD-180302 (2018).","journal-title":"J. Huntingtons. Dis."},{"key":"2694_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","volume":"9","author":"RM Bailey","year":"2018","unstructured":"Bailey, R. M., Armao, D., Nagabhushan Kalburgi, S. & Gray, S. J. Development of intrathecal AAV9 gene therapy for giant axonal neuropathy. Mol. Ther. Methods Clin. Dev. 9, 160\u2013171. https:\/\/doi.org\/10.1016\/j.omtm.2018.02.005 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2694_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ana.24332","volume":"77","author":"SI Duque","year":"2015","unstructured":"Duque, S. I. et al. A large animal model of spinal muscular atrophy and correction of phenotype. Ann. Neurol. 77, 399\u2013414. https:\/\/doi.org\/10.1002\/ana.24332 (2015).","journal-title":"Ann. Neurol."},{"key":"2694_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41591-019-0674-1","volume":"26","author":"M Bravo-Hernandez","year":"2020","unstructured":"Bravo-Hernandez, M. et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat. Med. 26, 118\u2013130. https:\/\/doi.org\/10.1038\/s41591-019-0674-1 (2020).","journal-title":"Nat. Med."},{"key":"2694_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1089\/hum.2017.151","volume":"29","author":"AM Bradbury","year":"2018","unstructured":"Bradbury, A. M. et al. AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (krabbe disease). Hum. Gene. Ther. 29, 785\u2013801. https:\/\/doi.org\/10.1089\/hum.2017.151 (2018).","journal-title":"Hum. Gene. Ther."},{"key":"2694_CR15","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/jnr.23882","volume":"94","author":"S Karumuthil-Melethil","year":"2016","unstructured":"Karumuthil-Melethil, S. et al. Intrathecal administration of AAV\/GALC vectors in 10\u201311-day-old twitcher mice improves survival and is enhanced by bone marrow transplant. J. Neurosci. Res. 94, 1138\u20131151. https:\/\/doi.org\/10.1002\/jnr.23882 (2016).","journal-title":"J. Neurosci. Res."},{"key":"2694_CR16","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1093\/hmg\/ddz127","volume":"28","author":"BL Gurda","year":"2019","unstructured":"Gurda, B. L. & Vite, C. H. Large animal models contribute to the development of therapies for central and peripheral nervous system dysfunction in patients with lysosomal storage diseases. Hum. Mol. Genet. 28, R119\u2013R131. https:\/\/doi.org\/10.1093\/hmg\/ddz127 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"2694_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/mtm.2013.7","volume":"1","author":"J Homs","year":"2014","unstructured":"Homs, J. et al. Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy. Mol. Ther. Methods Clin. Dev. 1, 7. https:\/\/doi.org\/10.1038\/mtm.2013.7 (2014).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2694_CR18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/gt.2014.103","volume":"22","author":"R Thwaite","year":"2015","unstructured":"Thwaite, R., Pages, G., Chillon, M. & Bosch, A. AAVrh. 10 immunogenicity in mice and humans Relevance of antibody cross-reactivity in human gene therapy. Gene. Ther. 22, 196\u2013201. https:\/\/doi.org\/10.1038\/gt.2014.103 (2015).","journal-title":"Gene. Ther."},{"key":"2694_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer, C. et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene. Ther. 29, 285\u2013298. https:\/\/doi.org\/10.1089\/hum.2018.015 (2018).","journal-title":"Hum. Gene. Ther."},{"key":"2694_CR20","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/mt.2009.71","volume":"17","author":"S Duque","year":"2009","unstructured":"Duque, S. et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 17, 1187\u20131196. https:\/\/doi.org\/10.1038\/mt.2009.71 (2009).","journal-title":"Mol. Ther."},{"key":"2694_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59\u201365. https:\/\/doi.org\/10.1038\/nbt.1515 (2009).","journal-title":"Nat. Biotechnol."},{"key":"2694_CR22","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/mt.2011.72","volume":"19","author":"SJ Gray","year":"2011","unstructured":"Gray, S. J. et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: A comparative study of adult mice and nonhuman primates. Mol. Ther. 19, 1058\u20131069. https:\/\/doi.org\/10.1038\/mt.2011.72 (2011).","journal-title":"Mol. Ther."},{"key":"2694_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.146832","volume":"1739","author":"RM Bailey","year":"2020","unstructured":"Bailey, R. M., Rozenberg, A. & Gray, S. J. Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies. Brain Res. 1739, 146832. https:\/\/doi.org\/10.1016\/j.brainres.2020.146832 (2020).","journal-title":"Brain Res."},{"key":"2694_CR24","doi-asserted-by":"publisher","first-page":"14051","DOI":"10.1038\/mtm.2014.51","volume":"1","author":"C Hinderer","year":"2014","unstructured":"Hinderer, C. et al. Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Mol. Ther. Methods Clin. Dev. 1, 14051. https:\/\/doi.org\/10.1038\/mtm.2014.51 (2014).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2694_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.omtm.2018.06.004","volume":"10","author":"J Hordeaux","year":"2018","unstructured":"Hordeaux, J. et al. Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing iduronate-2-sulfatase in rhesus macaques. Mol. Ther. Methods Clin. Dev. 10, 68\u201378. https:\/\/doi.org\/10.1016\/j.omtm.2018.06.004 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2694_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fnana.2014.00042","volume":"8","author":"DJ Schuster","year":"2014","unstructured":"Schuster, D. J. et al. Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat. 8, 42. https:\/\/doi.org\/10.3389\/fnana.2014.00042 (2014).","journal-title":"Front Neuroanat."},{"key":"2694_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.11.012","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Pre-clinical gene therapy with AAV9\/AGA in Aspartylglucosaminuria mice provides evidence for clinical translation. Mol. Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.012 (2020).","journal-title":"Mol. Ther."},{"key":"2694_CR28","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1093\/hmg\/ddz220","volume":"28","author":"G Pages","year":"2019","unstructured":"Pages, G. et al. Intrathecal AAVrh10 corrects biochemical and histological hallmarks of mucopolysaccharidosis VII mice and improves behavior and survival. Hum. Mol. Genet. 28, 3610\u20133624. https:\/\/doi.org\/10.1093\/hmg\/ddz220 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"2694_CR29","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.omtm.2020.04.012","volume":"17","author":"C Hinderer","year":"2020","unstructured":"Hinderer, C. et al. Translational feasibility of lumbar puncture for intrathecal AAV administration. Mol. Ther. Methods Clin. Dev. 17, 969\u2013974. https:\/\/doi.org\/10.1016\/j.omtm.2020.04.012 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2694_CR30","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172\u20131179. https:\/\/doi.org\/10.1038\/nn.4593 (2017).","journal-title":"Nat. Neurosci."},{"key":"2694_CR31","doi-asserted-by":"publisher","first-page":"E2421","DOI":"10.1073\/pnas.1522202113","volume":"113","author":"A Kagiava","year":"2016","unstructured":"Kagiava, A. et al. Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy. Proc. Natl. Acad. Sci. USA 113, E2421-2429. https:\/\/doi.org\/10.1073\/pnas.1522202113 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2694_CR32","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1523\/JNEUROSCI.3082-04.2005","volume":"25","author":"SS Scherer","year":"2005","unstructured":"Scherer, S. S. et al. Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice. J. Neurosci. 25, 1550\u20131559. https:\/\/doi.org\/10.1523\/JNEUROSCI.3082-04.2005 (2005).","journal-title":"J. Neurosci."},{"key":"2694_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41417-018-0077-3","volume":"26","author":"SG Ahmed","year":"2019","unstructured":"Ahmed, S. G., Abdelanabi, A., Doha, M. & Brenner, G. J. Schwannoma gene therapy by adeno-associated virus delivery of the pore-forming protein Gasdermin-D. Cancer Gene. Ther. 26, 259\u2013267. https:\/\/doi.org\/10.1038\/s41417-018-0077-3 (2019).","journal-title":"Cancer Gene. Ther."},{"key":"2694_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fnmol.2015.00036","volume":"8","author":"Y Tanguy","year":"2015","unstructured":"Tanguy, Y. et al. Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front. Mol. Neurosci. 8, 36. https:\/\/doi.org\/10.3389\/fnmol.2015.00036 (2015).","journal-title":"Front. Mol. Neurosci."},{"key":"2694_CR35","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/jgm.1496","volume":"12","author":"C Hu","year":"2010","unstructured":"Hu, C., Busuttil, R. W. & Lipshutz, G. S. RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J. Gene. Med. 12, 766\u2013778. https:\/\/doi.org\/10.1002\/jgm.1496 (2010).","journal-title":"J. Gene. Med."},{"key":"2694_CR36","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/mt.2011.98","volume":"19","author":"H Zhang","year":"2011","unstructured":"Zhang, H. et al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 19, 1440\u20131448. https:\/\/doi.org\/10.1038\/mt.2011.98 (2011).","journal-title":"Mol. Ther."},{"key":"2694_CR37","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/art.41314","volume":"72","author":"S Chakrabarti","year":"2020","unstructured":"Chakrabarti, S. et al. Intraarticular adeno-associated virus serotype AAV-PHP.S-mediated chemogenetic targeting of knee-innervating dorsal root ganglion neurons alleviates inflammatory pain in mice. Arthritis. Rheumatol. 72, 1749\u20131758. https:\/\/doi.org\/10.1002\/art.41314 (2020).","journal-title":"Arthritis. Rheumatol."},{"key":"2694_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.672449","volume":"12","author":"TB Bertolini","year":"2021","unstructured":"Bertolini, T. B. et al. Effect of CpG depletion of vector genome on CD8(+) T cell responses in AAV gene therapy. Front Immunol. 12, 672449. https:\/\/doi.org\/10.3389\/fimmu.2021.672449 (2021).","journal-title":"Front Immunol."},{"key":"2694_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.675897","volume":"12","author":"BA Hamilton","year":"2021","unstructured":"Hamilton, B. A. & Wright, J. F. Challenges posed by immune responses to AAV vectors: addressing root causes. Front Immunol. 12, 675897. https:\/\/doi.org\/10.3389\/fimmu.2021.675897 (2021).","journal-title":"Front Immunol."},{"key":"2694_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ana.24441","volume":"78","author":"I Sargiannidou","year":"2015","unstructured":"Sargiannidou, I. et al. Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease. Ann. Neurol. 78, 303\u2013316. https:\/\/doi.org\/10.1002\/ana.24441 (2015).","journal-title":"Ann. Neurol."},{"key":"2694_CR41","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/hmg\/ddy056","volume":"27","author":"A Kagiava","year":"2018","unstructured":"Kagiava, A. et al. Intrathecal gene therapy in mouse models expressing CMT1X mutations. Hum. Mol. Genet. 27, 1460\u20131473. https:\/\/doi.org\/10.1093\/hmg\/ddy056 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"2694_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198154","volume":"13","author":"AI Ramsingh","year":"2018","unstructured":"Ramsingh, A. I. et al. Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulation. PLoS ONE 13, e0198154. https:\/\/doi.org\/10.1371\/journal.pone.0198154 (2018).","journal-title":"PLoS ONE"},{"key":"2694_CR43","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1089\/hum.2019.012","volume":"30","author":"J Hordeaux","year":"2019","unstructured":"Hordeaux, J. et al. Safe and sustained expression of human iduronidase after intrathecal administration of adeno-associated virus serotype 9 in infant rhesus monkeys. Hum. Gene. Ther. 30, 957\u2013966. https:\/\/doi.org\/10.1089\/hum.2019.012 (2019).","journal-title":"Hum. Gene. Ther."},{"key":"2694_CR44","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","volume":"13","author":"WM Pardridge","year":"2016","unstructured":"Pardridge, W. M. CSF, blood-brain barrier, and brain drug delivery. Exp. Opin. Drug. Deliv. 13, 963\u2013975. https:\/\/doi.org\/10.1517\/17425247.2016.1171315 (2016).","journal-title":"Exp. Opin. Drug. Deliv."},{"key":"2694_CR45","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.286","author":"LV Gushchina","year":"2021","unstructured":"Gushchina, L. V. et al. Lack of toxicity in non-human primates receiving clinically relevant doses of an AAV9U7snRNA vector designed to induce DMD exon 2 skipping. Hum. Gene. Ther. https:\/\/doi.org\/10.1089\/hum.2020.286 (2021).","journal-title":"Hum. Gene. Ther."},{"key":"2694_CR46","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ymthe.2020.07.009","volume":"28","author":"L Morales","year":"2020","unstructured":"Morales, L., Gambhir, Y., Bennett, J. & Stedman, H. H. Broader implications of progressive liver dysfunction and lethal sepsis in two boys following systemic high-dose AAV. Mol. Ther. 28, 1753\u20131755. https:\/\/doi.org\/10.1016\/j.ymthe.2020.07.009 (2020).","journal-title":"Mol. Ther."},{"key":"2694_CR47","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","volume":"11","author":"G Ronzitti","year":"2020","unstructured":"Ronzitti, G., Gross, D. A. & Mingozzi, F. Human immune responses to adeno-associated virus (AAV) vectors. Front Immunol. 11, 670. https:\/\/doi.org\/10.3389\/fimmu.2020.00670 (2020).","journal-title":"Front Immunol."},{"key":"2694_CR48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","volume":"4","author":"R Calcedo","year":"2013","unstructured":"Calcedo, R. & Wilson, J. M. Humoral immune response to AAV. Front Immunol. 4, 341. https:\/\/doi.org\/10.3389\/fimmu.2013.00341 (2013).","journal-title":"Front Immunol."},{"key":"2694_CR49","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/sj.gt.3300938","volume":"6","author":"S Zolotukhin","year":"1999","unstructured":"Zolotukhin, S. et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973\u2013985. https:\/\/doi.org\/10.1038\/sj.gt.3300938 (1999).","journal-title":"Gene Ther."},{"key":"2694_CR50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/hgtb.2014.120","volume":"26","author":"J Piedra","year":"2015","unstructured":"Piedra, J. et al. Development of a rapid, robust, and universal picogreen-based method to titer adeno-associated vectors. Hum. Gene. Ther. Methods 26, 35\u201342. https:\/\/doi.org\/10.1089\/hgtb.2014.120 (2015).","journal-title":"Hum. Gene. Ther. Methods"},{"key":"2694_CR51","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-1-4939-7862-5_22","volume":"1791","author":"A Kagiava","year":"2018","unstructured":"Kagiava, A. & Kleopa, K. A. Intrathecal delivery of viral vectors for gene therapy. Methods Mol. Biol. 1791, 277\u2013285. https:\/\/doi.org\/10.1007\/978-1-4939-7862-5_22 (2018).","journal-title":"Methods Mol. Biol."},{"key":"2694_CR52","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1093\/hmg\/ddz199","volume":"28","author":"A Kagiava","year":"2019","unstructured":"Kagiava, A. et al. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. Hum. Mol. Genet. 28, 3528\u20133542. https:\/\/doi.org\/10.1093\/hmg\/ddz199 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"2694_CR53","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/jnr.21561","volume":"86","author":"M Ahn","year":"2008","unstructured":"Ahn, M. et al. Cx29 and Cx32, two connexins expressed by myelinating glia, do not interact and are functionally distinct. J. Neurosci. Res. 86, 992\u20131006. https:\/\/doi.org\/10.1002\/jnr.21561 (2008).","journal-title":"J. Neurosci. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02694-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02694-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02694-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:00:37Z","timestamp":1670090437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02694-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2694"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-02694-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"assertion":[{"value":"19 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23358"}}